Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. scores highest on Torque (96) and lowest on Price (0). Its PosiPenta is 49.33 out of 100, around the middle of similar companies.
On the Penta Grid this week, Outlook Therapeutics, Inc. is Grid #296 of 837 in the Healthcare sector in United States, and Grid #1,952 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Outlook Therapeutics, Inc. | 49.33 | 0 | 64 | 30 | 96 | 57 |
| Cue Biopharma, Inc. | 27.08 | 1 | 41 | 45 | 8 | 41 |
| AN2 Therapeutics, Inc. | 47.49 | 32 | 43 | 54 | 68 | 40 |
| Atrium Therapeutics, Inc. | 41.91 | 44 | 15 | 31 | 77 | 43 |
| Quanterix Corporation | 43.19 | 45 | 41 | 34 | 49 | 48 |
| WW International, Inc. | 53.66 | 94 | 53 | 37 | 36 | 48 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -0.70 |
| P/B ratio | -11.44 |
EEarnings
| Trailing EPS | ₹-66.30 |
| Forward EPS | ₹-11.37 |
NNitro
| Price | 46.24 |
| 52-week high | 240.39 |
| 52-week low | 15.25 |
| Fall from 52-week high | 80.8% |
TTorque
| Return on equity (ROE) | — |
| Debt-to-equity | -0.94 |
AAnchor
| Beta (price swings) | 0.67 |
| Market cap | ₹1,125 Cr |
| Insider holding | 12.64% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Outlook Therapeutics, Inc.'s PosiPenta score?
Outlook Therapeutics, Inc.'s PosiPenta is 49.33 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Outlook Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Outlook Therapeutics, Inc. is Grid #296 of 837 in the Healthcare sector in United States, and Grid #1,952 of 4,000 in United States.
Which PosiPenta pillar is strongest for Outlook Therapeutics, Inc.?
Torque (durability), with a score of 96 out of 100: much better than most similar companies.
Which PosiPenta pillar is weakest for Outlook Therapeutics, Inc.?
Price (valuation), with a score of 0 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.